Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin in Advanced Serous Ovarian Cancer
NCT01081951Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of olaparib in ovarian cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival at 20 months. Started Feb 2010; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01081951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01081951.